BEIJING - Tasly Pharmaceutical Group Co Ltd, a leading pharmaceutical company in China, said Saturday that its net profit in the first half of the year rose 24.04 percent year on year to 744.5 million yuan ($120.9 million).

Business revenues rose 13.07 percent from a year earlier to 6.1 billion yuan, according to the company's interim report.

Earning per share for the period stood at 0.72 yuan.

Tasly is one of China's largest producers of traditional Chinese medicines. Its business scope also includes chemical and biological drugs, healthcare products, and functional foods.

Pharmaceutical sector ripe for innovation	Cloud initiative helps promote health service